ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
14.16
+2.15 (17.90%)
At close: Jan 30, 2026, 4:00 PM EST
12.77
-1.39 (-9.82%)
After-hours: Jan 30, 2026, 7:59 PM EST
ProMIS Neurosciences Employees
As of December 31, 2024, ProMIS Neurosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$3,660,408
Market Cap
30.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2021 | 6 | 5 | 500.00% | 5 | 1 |
| Dec 31, 2020 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Boundless Bio | 64 |
| CollPlant Biotechnologies | 57 |
| Senti Biosciences | 34 |
| Palatin Technologies | 29 |
| Daré Bioscience | 23 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
PMN News
- 1 day ago - ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - GlobeNewsWire
- 6 weeks ago - ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease - GlobeNewsWire
- 7 weeks ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire